Net Loss Per Share Attributable to Common Stockholders (Tables)

3 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Weighted-Average Common Stock Equivalents Excluded from Calculation of Diluted Net Loss Per Share as They Had Anti-Dilutive Effect

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented as they had an anti-dilutive effect:

	Three Months Ended March 31,
	2019		2018
Preferred stock (if converted)		-		7,039,155
Options to purchase common stock		432,051		424,843
Contingently issuable common stock upon exchange of    Vaccinex Products, LP units		1,202,566		1,202,566
Contingently issuable common stock upon exchange of    VX3 units		1,318,797		800,880